Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01975636 · ClinicalTrials.gov registry record · Phase 1
An Open-label, Single Dose Study to Determine the Metabolism and Elimination of [14C]E2609 in Healthy Male Subjects
A Phase 1 study of Metabolism and Elimination, sponsored by Eisai.
- Completed
- Registry status
- Phase 1
- Development phase
- 113
- Enrollment target
- 2
- Study locations
NCT01975636 is a Phase 1 study of Metabolism and Elimination that has completed, run by Eisai. The registered enrollment target is 113 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT01975636, a Phase 1 study of Metabolism and Elimination, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 113 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is an open-label, single dose study in healthy male subjects.
Conditions Studied
Interventions
- DRUG E2609
Study Locations (2)
Wisconsin
- Covance Clinical Research Unit Inc. - Madison
- Covance Laboratories - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 113 participants |
| Start Date | 2013-06 |
| Est. Completion | 2014-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01975636
The ClinicalTrials.gov registry entry for NCT01975636 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 113 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metabolism and Elimination appearing as the primary indexed condition, and to 1 intervention - of which E2609 is the first listed.
NCT01975636 reports 2 study locations spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT01975636 about?
NCT01975636 is a clinical study titled "An Open-label, Single Dose Study to Determine the Metabolism and Elimination of [14C]E2609 in Healthy Male Subjects". This is an open-label, single dose study in healthy male subjects.
What is the current status of trial NCT01975636?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 113 participants. The study started on 2013-06. Estimated completion is 2014-03.
What conditions does trial NCT01975636 study?
This clinical trial studies the following conditions: Metabolism and Elimination.
What interventions are being tested in trial NCT01975636?
The interventions under investigation include: E2609 (DRUG).
Who is sponsoring clinical trial NCT01975636?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01975636 being conducted?
This trial has 2 study locations across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.